{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:05:22Z","timestamp":1781276722185,"version":"3.54.1"},"reference-count":156,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2023KY210"],"award-info":[{"award-number":["2023KY210"]}]},{"name":"Hangzhou Normal University Graduate Student Research Program","award":["2022HSDYJSKY246"],"award-info":[{"award-number":["2022HSDYJSKY246"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/13543776.2025.2462834","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T12:46:21Z","timestamp":1739537181000},"page":"387-408","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Updated patent review for hematopoietic progenitor kinase (HPK1) inhibitors and degraders (2021-present)"],"prefix":"10.1080","volume":"35","author":[{"given":"Ying-Hui","family":"Yuan","sequence":"first","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ying","family":"Mao","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Fan","family":"Yue","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Lan","family":"He","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Hui","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yin","sequence":"additional","affiliation":[{"name":"Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshe","family":"Wang","sequence":"additional","affiliation":[{"name":"Drug Discovery, Hangzhou Purple Crystal Pharma","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3739-0930","authenticated-orcid":false,"given":"Xiang-Yang","family":"Ye","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,2,16]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.10.18.2251"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb01093.x"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114819"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1416"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.310946"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0089"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e318215c3fb"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0761-0"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.012186"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2011.621"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.26.4.1297-1306.2006"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3083"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.2.1359"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101485200"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0570-5"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7494"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00172"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204224"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.4.529"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2020.107662"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008343200"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600894"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.001"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111433"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211062524"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3690892"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-451385"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-489856"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040313"},{"key":"e_1_3_4_32_1","unstructured":"University Health Network. Treatment for acute myeloid leukemia or lymphoma using 4-amino-5-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)thieno[2 3-b]pyridin-6(7H)-one or pharmaceutically acceptable salts thereof. WO2023115211A1. 2023."},{"key":"e_1_3_4_33_1","unstructured":"University Health Network. Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)thieno[2 3-b]pyridin-6(7H)-one. WO2021226707A1. 2021."},{"key":"e_1_3_4_34_1","unstructured":"Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Preparation of deuterium-modified thienopyridine ketone compound as HPK1 inhibitor. WO2022111517A1. 2022."},{"key":"e_1_3_4_35_1","unstructured":"Shandong Xuanzhu Pharma Co. Ltd. Preparation of tricyclic HPK1 inhibitor and use thereof. WO2022188823A1. 2022."},{"key":"e_1_3_4_36_1","unstructured":"Bristol-Myers Squibb Company. Furanone compounds useful as HPK1 inhibitors in the treatment of cancer and viral infections and their preparation. WO2019090198A1. 2019."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1924671"},{"key":"e_1_3_4_38_1","unstructured":"Suzhou Sinovent Pharmaceuticals Co. Ltd. Preparation of arylamines as hematopoietic progenitor kinase inhibitor. CN114805330A. 2022."},{"key":"e_1_3_4_39_1","unstructured":"Guangdong Newopp Biopharmaceuticals Co. Ltd. Synthesis of Heterocyclic HPK1 inhibitors as anticancer agents. WO2022188735A1. 2022."},{"key":"e_1_3_4_40_1","unstructured":"Lomond Therapeutics Inc. Preparation of N-arylpyrimidin-2-amine derivatives as therapeutic agents. WO2023043630A1. 2023."},{"key":"e_1_3_4_41_1","unstructured":"Shanghai Jiao Tong University. Preparation of pyrimidine derivatives as HPK1 inhibitors. CN116217561A. 2023."},{"key":"e_1_3_4_42_1","unstructured":"Silexon AI Technology Co. Ltd. Pyrimidine derivatives as HPK1 inhibitors and their preparation. WO2023138612A1. 2023."},{"key":"e_1_3_4_43_1","unstructured":"Nanjing Damei Biopharmaceutical Co. Ltd. Preparation of phenyl-hetero[2 3-d]pyrimidin-2-amine derivatives as HPK1 receptor inhibitors for treatment of cancer. CN116462680A. 2023."},{"key":"e_1_3_4_44_1","unstructured":"Qilu Regor Therapeutics Inc. Preparation of substituted tetrahydroisoquinolinylaminopyridines and pyrrolopyridinylphenyldialkyl phosphine and their analogs as HPK1 inhibitors for treating cancers. WO2021000935A1. 2021."},{"key":"e_1_3_4_45_1","unstructured":"Qilu Regor Therapeutics Inc. Preparation of N-substituted-indolin-3-ylacetic acid compounds as HPK1 inhibitors and uses thereof. WO2022002237A1. 2022."},{"key":"e_1_3_4_46_1","unstructured":"Merck Sharp & Dohme Corp. Preparation of diaminopyrimidine carboxamide inhibitors of HPK1. WO2022098809A1. 2022."},{"key":"e_1_3_4_47_1","unstructured":"Nanjing Hongyun Biotechnology Co. Ltd. HPK1 kinase modulator preparation method therefor and application thereof. WO2022100688A1. 2022."},{"key":"e_1_3_4_48_1","unstructured":"Adlai Nortye Biopharma Co. Ltd. HPK1 kinase inhibitor compound. WO2022199561A1. 2022."},{"key":"e_1_3_4_49_1","unstructured":"Adlai Nortye Biopharma Co. Ltd. Preparation of HPK1 kinase inhibitors. WO2022214009A1. 2022."},{"key":"e_1_3_4_50_1","unstructured":"Adlai Nortye Biopharma Co. Ltd. Pyrimidine-1 6-naphthyridine derivatives as highly active HPK1 kinase inhibitors and their preparation pharmaceutical compositions and use in the treatment of cancer inflammation and autoimmune diseases. WO2022214008A1. 2022."},{"key":"e_1_3_4_51_1","unstructured":"Glenmark Specialty SA. Pyrimidine compounds for use as MAP4K1 inhibitors. WO2023281417A1. 2023."},{"key":"e_1_3_4_52_1","unstructured":"Voronoi Bio Inc. Preparation of isoxazolidine derivative as CDK inhibitors for treatment of cancer. WO2022131741A1. 2022."},{"key":"e_1_3_4_53_1","unstructured":"Wigen Biomedicine Technology (Shanghai) Co. Ltd. Fused ring compound as HPK1 inhibitor. WO2023083299A1. 2023."},{"key":"e_1_3_4_54_1","unstructured":"Wigen Biomedicine Technology (Shanghai) Co. Ltd. Preparation of fused ring compounds serving as HPK1 inhibitors. WO2023134608A1. 2023."},{"key":"e_1_3_4_55_1","unstructured":"BeiGene L. Preparation of aminopyrazine compounds as HPK1 inhibitor and the use thereof. WO2021032148A1. 2021."},{"key":"e_1_3_4_56_1","unstructured":"BeiGene Ltd. Preparation of 3-[(1H-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and application. WO2022068848A1. 2022."},{"key":"e_1_3_4_57_1","unstructured":"Betta Pharmaceuticals Co. Ltd. Preparation of nitrogen-containing heterocyclic compounds as HPK1 inhibitor. CN115197132A. 2022."},{"key":"e_1_3_4_58_1","unstructured":"Betta Pharmaceuticals Co. Ltd. Preparation of pyrazine-based compounds as HPK1 inhibitor. CN116102550A. 2023."},{"key":"e_1_3_4_59_1","unstructured":"Betta Pharmaceuticals Co. Ltd. Preparation of pyrazine derivatives as HPK1 inhibitor and its application in medicine. CN116082307A. 2023."},{"key":"e_1_3_4_60_1","unstructured":"AstraZeneca AB. Preparation of substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer. WO2023001794A1. 2023."},{"key":"e_1_3_4_61_1","unstructured":"Ontario Institute for Cancer Research (OICR). Preparation of halo-substituted amino aza-heteroaryl compounds as inhibitors of the hematopoietic progenitor kinase 1 (HPK1). WO2022226665A1. 2022."},{"key":"e_1_3_4_62_1","unstructured":"Ontario Institute for Cancer Research (OICR). Preparation of substituted amino aza-heteroaryl compounds as inhibitors of the hematopoietic progenitor kinase 1 (HPK1). WO2022226666A1. 2022."},{"key":"e_1_3_4_63_1","unstructured":"Zhuhai Yufan Biotechnologies Co. Ltd. Application of HPK1 kinase inhibitor in prevention and\/or treatment of pathogenic infection in animal. CN113797202A. 2021."},{"key":"e_1_3_4_64_1","unstructured":"Zhuhai Yufan Biotechnologies Co. Ltd. Applications of HPK1 kinase inhibitor in preventing and\/or treating animal pathogen infection. WO2021254118A1. 2021."},{"key":"e_1_3_4_65_1","unstructured":"Zhuhai Yufan Biotechnologies Co. Ltd. Preparation of deuterated thiazole or pyrazole derivatives as HPK1 kinase inhibitors. WO2022089225A1. 2022."},{"key":"e_1_3_4_66_1","unstructured":"Bayer Aktiengesellschaft. Preparation of spiro compounds as Map4K1 inhibitors. WO2022167627A1. 2022."},{"key":"e_1_3_4_67_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pyridine compound pharmaceutical composition including the same and preparing method and application thereof. CN114181257A. 2022."},{"key":"e_1_3_4_68_1","unstructured":"Ontario Institute for Cancer Research (OICR). Preparation of substituted amino pyridine compounds as inhibitors of the hematopoietic progenitor kinase 1 (HPK1). WO2022226667A1. 2022."},{"key":"e_1_3_4_69_1","unstructured":"Ontario Institute for Cancer Research (OICR). Preparation of halo-substituted aminopyridine compounds as inhibitors of the hematopoietic progenitor kinase 1 (HPK1). WO2022226668A1. 2022."},{"key":"e_1_3_4_70_1","unstructured":"Shanghai Jiao Tong University. Preparation of five-membered aromatic heterocyclic piperidine\/homopiperidine compound as HPK1 inhibitor for treating tumors. CN116535422A. 2023."},{"key":"e_1_3_4_71_1","unstructured":"Zhuhai Yufan Biotechnologies Co. Ltd. Preparation of heteroarylamines as HPK1 inhibitors for treatment of cancers. WO2019206049A1. 2019."},{"key":"e_1_3_4_72_1","unstructured":"Shenzhen Ionova Life Science Co. Ltd. Preparation of pyrimidine and pyridine derivatives as HPK1 modulator and methods using same. WO2022063140A1. 2022."},{"key":"e_1_3_4_73_1","unstructured":"Blueprint Medicines Corporation. Nitrogen-containing heteroarylamines as MAP4K1 inhibitors and their preparation. WO2021146370A1. 2021."},{"key":"e_1_3_4_74_1","unstructured":"Blueprint Medicines Corporation. Preparation of 2-amino-7 8-dihydro-5H-pyrano[4 3-b]pyridin-5-one compounds as MAP4K1 inhibitors. WO2022192145A1. 2022."},{"key":"e_1_3_4_75_1","unstructured":"Blueprint Medicines Corporation. Heterocyclic compounds as MAP4K1 inhibitors and their preparation. WO2023288254A1. 2023."},{"key":"e_1_3_4_76_1","unstructured":"Blueprint Medicines Corporation. Heterocyclic compounds as MAP4K1 inhibitors and their preparation. WO2023288264A1. 2023."},{"key":"e_1_3_4_77_1","unstructured":"Jiangsu Simcere Pharmaceutical Co. Ltd. Preparation of heterocyclic compounds as HPK1 inhibitors. CN116265470A. 2023."},{"key":"e_1_3_4_78_1","unstructured":"Guangdong Newopp Biopharmaceuticals Co. Ltd. Heterocyclic compounds as inhibitors of HPK1. WO2021004547Al. 2021."},{"key":"e_1_3_4_79_1","unstructured":"Adlainortye Biopharma Co. Ltd. High activity HPK1 kinase inhibitor. WO2022089398A1. 2022."},{"key":"e_1_3_4_80_1","unstructured":"Merck Shapp & Dohme Corp. 7-oxazole substituted 2-aminoquinazoline inhibitors of HPK1. WO2022098807A1. 2022."},{"key":"e_1_3_4_81_1","unstructured":"Merck Shapp & Dohme Corp. 7-phenyl substituted 2-aminoquinazoline inhibitors of HPK1. WO2022098806A1. 2022."},{"key":"e_1_3_4_82_1","unstructured":"AipetPartner (Beijing) Co. Ltd. Use of HPK1 inhibitor in treatment of interferon-related diseases. WO2023161844A1. 2023."},{"key":"e_1_3_4_83_1","unstructured":"Nanjing Zheng Xiang Pharmaceuticals Co. Ltd. Cinnolines as inhibitors of HPK1. WO2021004535A1. 2021."},{"key":"e_1_3_4_84_1","unstructured":"Ennova-Bio (Zhejiang) Pharmaceutical Co. Ltd. Novel HPK1 inhibitor and preparation method thereof and application thereof. CN113336747A. 2021."},{"key":"e_1_3_4_85_1","unstructured":"Ennova-Bio (Zhejiang) Pharmaceutical Co. Ltd. Novel HPK1 inhibitor and preparation method thereof and application thereof. WO2021175271A1. 2021."},{"key":"e_1_3_4_86_1","unstructured":"Shenzhen Zhiyao Information Technology Co. Ltd. HPK1 inhibitor and use thereof. CN114516857A. 2022."},{"key":"e_1_3_4_87_1","unstructured":"Suzhou Sinoway Pharmaceutical Technology Co. Ltd. Heterocyclic compound preparation method pharmaceutical composition and application thereof. CN114907374A. 2022."},{"key":"e_1_3_4_88_1","unstructured":"Zhe Jiang Hisun Pharmaceutical Co. Ltd. Aromatic condensed ring derivative preparation method thereof and use thereof. WO2022222951A1. 2022."},{"key":"e_1_3_4_89_1","unstructured":"China Pharmaceutical University. Compound used as HPK1 kinase inhibitor preparation method and use thereof. CN114853730A. 2022."},{"key":"e_1_3_4_90_1","unstructured":"China Pharmaceutical University. Compound used as HPK1 kinase inhibitor preparation method and use thereof. CN115772156A. 2023."},{"key":"e_1_3_4_91_1","unstructured":"Merck Patent Gmbh. Pyrido[3 2-d]pyrimidine as HPK1 inhibitors. WO2023201185A1. 2023."},{"key":"e_1_3_4_92_1","unstructured":"Nimbus Saturn Inc. HPK1 antagonists and uses thereof. WO2022174253A1. 2022."},{"key":"e_1_3_4_93_1","unstructured":"Beijing Wangshi Wisdom Technology Co. Ltd. HPK1 inhibitor preparation method and use thereof. CN116063329A. 2023."},{"key":"e_1_3_4_94_1","unstructured":"Jiangsu Xiansheng Pharmaceutical Co. Ltd. Lactam compounds as HPK1 inhibitors and their applications. CN116023378A. 2023."},{"key":"e_1_3_4_95_1","unstructured":"Insilico Medicine IP Ltd. HPK1 antagonists and uses thereof. WO2023193759A1. 2023."},{"key":"e_1_3_4_96_1","unstructured":"Sichuan Coren Bottey Bio-pharmaceutical Company Limited. Pyrazolo-ring compound pharmaceutical composition containing the same preparation method and uses thereof. CN113845531A. 2021."},{"key":"e_1_3_4_97_1","unstructured":"Lomond Therapeutics Inc. Compounds with 1H-pyrazolo[4 3-c]pyridine-6-amino as therapeutic agents. WO2023278483A1. 2023."},{"key":"e_1_3_4_98_1","unstructured":"Incyte Corporation. Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer. WO2018049214A1. 2018."},{"key":"e_1_3_4_99_1","unstructured":"Hangzhou Medical College. Pyrazolo [3 4-b] pyridine derivatives preparation method and application as HPK1 inhibitor thereof. CN113861188A. 2021."},{"key":"e_1_3_4_100_1","unstructured":"Hangzhou Medical College. HPK1 and\/or LCK kinase regulator preparation method and uses thereof. CN116162087A. 2023."},{"key":"e_1_3_4_101_1","unstructured":"Rapt Therapeutics Inc. lH-pyrazolo[3 4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor cell kinase 1 (HPK1) modulators and\/or inhibitors for the treatment of cancer and other diseases. WO2022197641A1. 2022."},{"key":"e_1_3_4_102_1","unstructured":"1ST Biotherapeutics Inc. Indazole as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods of using same. WO2022064458A1. 2022."},{"key":"e_1_3_4_103_1","unstructured":"1ST Biotherapeutics Inc. Indazole as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods of using same. WO2022064459A1. 2022."},{"key":"e_1_3_4_104_1","unstructured":"Ennova-Bio (Zhejiang) Pharmaceutical Co. Ltd. Novel HPK1 inhibitor preparation method and uses thereof. CN115433161A. 2022."},{"key":"e_1_3_4_105_1","unstructured":"Ennova-Bio (Zhejiang) Pharmaceutical Co. Ltd. Compound having kinase inhibitory function and preparation method thereof and application thereof. WO2022253328A1. 2022."},{"key":"e_1_3_4_106_1","unstructured":"Broadenbio Co. Ltd. Pyrazolopyridazinone compound pharmaceutical composition and use thereof. CN114437074A. 2022."},{"key":"e_1_3_4_107_1","unstructured":"Broadenbio Co. Ltd. Pyrazolopyridazinone compound pharmaceutical composition and use thereof. WO2022095904A1. 2022."},{"key":"e_1_3_4_108_1","unstructured":"Beigene Ltd. Pyrrolo[2 3-b]pyridines as HPK1 inhibitor and uses thereof. WO2020103896A1. 2020."},{"key":"e_1_3_4_109_1","unstructured":"Beigene Ltd. Pyrrolo[2 3-b]pyridines as HPK1 inhibitor and the use thereof. WO2021000925A1. 2021."},{"key":"e_1_3_4_110_1","unstructured":"Baekje Shenzhou (Beijing) Biotechnology Co. Ltd. Preparation method of tricyclic compound as HPK1 inhibitor. CN112239473A. 2021."},{"key":"e_1_3_4_111_1","unstructured":"Jingsu Simcere Pharmaceutical Co. Ltd. Pyropyridine compounds and application thereof. CN114685490A. 2022."},{"key":"e_1_3_4_112_1","unstructured":"Jingsu Simcere Pharmaceutical Co. Ltd. Multisubstituted Nitrogen-containing heterocyclic compounds and application thereof. CN114685489A. 2022."},{"key":"e_1_3_4_113_1","unstructured":"Jingsu Simcere Pharmaceutical Co. Ltd. Bicyclic compounds as HPK1 inhibitor and application thereof. WO2022171034A1. 2022."},{"key":"e_1_3_4_114_1","unstructured":"Jingsu Simcere Pharmaceutical Co. Ltd. Alkynes compound as HPK1 inhibitor and use thereof. WO2022228522A1. 2022."},{"key":"e_1_3_4_115_1","unstructured":"Evopoint Biosciences Co. Ltd. Nitrogen-containing heterocyclic compound. WO2022237830A1. 2022."},{"key":"e_1_3_4_116_1","unstructured":"Evopoint Biosciences Co. Ltd. Nitrogen-containing heterocyclic compound. CN115490686A. 2022."},{"key":"e_1_3_4_117_1","unstructured":"Beida Pharmaceutical Co. Ltd. HPK1 inhibitor and application thereof in medicine. CN115894480A. 2023."},{"key":"e_1_3_4_118_1","unstructured":"Wuhan Renfu Innovation Drug R&D Center Co. Ltd. HPK1 inhibitor and application thereof. CN115433184A. 2022."},{"key":"e_1_3_4_119_1","unstructured":"China Pharmaceutical University. Compound of hematopoietic progenitor cell kinase 1 (HPK1) inhibitor preparation method and application thereof. CN116143779A. 2023."},{"key":"e_1_3_4_120_1","unstructured":"Wigen Biomedical Technology (Shanghai) Co. Ltd. Fused ring compound as HPK1 inhibitor. WO2023083282A1. 2023."},{"key":"e_1_3_4_121_1","unstructured":"Genfleet Therapeutics (Shanghai) Inc. Fused ring-substituted six-membered heterocyclic compound and preparation method thereof and use thereof. WO2023131122A1. 2023."},{"key":"e_1_3_4_122_1","unstructured":"Biofront Ltd (Cayman). HPK1 inhibitors compositions containing HPK1 inhibitor and methods of using same. WO2023023942A1. 2023."},{"key":"e_1_3_4_123_1","unstructured":"Biofront Ltd (Cayman). Kinase modulators compositions containing the kinase modulator and methods of using same. WO2023025092A1. 2023."},{"key":"e_1_3_4_124_1","unstructured":"Beigene Ltd. Pyrrolo[2 3-b]pyrazines as HPK1 inhibitor and the use thereof. WO2021000925A. 2021."},{"key":"e_1_3_4_125_1","unstructured":"Hangzhou Zhongmeihuadong Pharmaceutical Co. Ltd. Pyrrole fused-ring pyrazole compound and preparation method thereof and use thereof. WO2023131271A1. 2023."},{"key":"e_1_3_4_126_1","unstructured":"Pfizer Inc. Isoindolone compounds as HPK1 inhibitors. WO2021224818A1. 2021."},{"key":"e_1_3_4_127_1","unstructured":"Renxuanzhu (Beijing) Pharmaceutical Technology Co. Ltd. HPK1 inhibitor and uses thereof. CN114940683A. 2022."},{"key":"e_1_3_4_128_1","unstructured":"Renxuanzhu (Beijing) Pharmaceutical Technology Co. Ltd. HPK1 inhibitor and uses thereof. CN115611925A. 2023."},{"key":"e_1_3_4_129_1","unstructured":"Hangzhou Yingchuang Medicine Technology Co. Ltd. Heterocyclic compounds as HPK1 inhibitors. CN115536656A. 2022."},{"key":"e_1_3_4_130_1","unstructured":"Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Fused bicyclic compound containing pyrrolidone. WO2023160577A1. 2023."},{"key":"e_1_3_4_131_1","unstructured":"Sichuan Kelunbotai Biomedical Co. Ltd. Heterocyclic lactam compound pharmaceutical composition containing the same and application thereof. CN115557946A. 2023."},{"key":"e_1_3_4_132_1","unstructured":"Pfizer Inc. Azalactam compounds as HPK1 inhibitors. WO2021220185A1. 2021."},{"key":"e_1_3_4_133_1","unstructured":"Zhejiang Hisun Pharmaceutical Co. Ltd. pyndolactam derivative and preparation method thereof and application of pharmaceutical composition containing the same in medicine. CN115806553A. 2023."},{"key":"e_1_3_4_134_1","unstructured":"Zhejiang Hisun Pharmaceutical Co. Ltd. Pyridolactam derivative and preparation method and use thereof. WO2023030478A1. 2023."},{"key":"e_1_3_4_135_1","unstructured":"Nimbus Saturn Inc. HPK1 antagonists and uses thereof. WO2021050964A1. 2021."},{"key":"e_1_3_4_136_1","unstructured":"Nimbus Saturn Inc. HPK1 antagonists and uses thereof. WO2022187856A1. 2022."},{"key":"e_1_3_4_137_1","unstructured":"Nimbus Saturn Inc. HPK1 antagonists and uses thereof. WO2022213062A1. 2022."},{"key":"e_1_3_4_138_1","unstructured":"Nimbus Saturn Inc. HPK1 antagonists and uses thereof. WO2023015199A1. 2023."},{"key":"e_1_3_4_139_1","unstructured":"Chengdu Baiyu Pharmaceutical Co. Ltd. Indolinone derivatives and use thereof in medicines. WO2023186137A1. 2023."},{"key":"e_1_3_4_140_1","unstructured":"Chengdu Baiyu Pharmaceutical Co. Ltd. Azaindolone derivatives and use thereof in medicines. CN115703798A. 2023."},{"key":"e_1_3_4_141_1","unstructured":"Beigene Ltd. Preparation of pyrrolo[2 3-b]pyridines or pyrrolo[2 3-b]pyrazines as HPK1 inhibitor and the use thereof. WO2019238067A1. 2019."},{"key":"e_1_3_4_142_1","unstructured":"Hangzhou Zhongmeihuadong Pharmaceutical Co. Ltd. Pyrrolopyrimidine derivative and preparation method thereof and use thereof. WO2022166920A1. 2022."},{"key":"e_1_3_4_143_1","unstructured":"Bayer Aktiengesellschaft. Spiro-fused tricyclic MAP4K1 inhibitor. WO2021074279A1. 2021."},{"key":"e_1_3_4_144_1","unstructured":"Jiangsu Hengrui Pharmaceutical Co. Ltd. Fused tetracyclic compound preparation method thereof and application thereof in medicine. CN114907377A. 2022."},{"key":"e_1_3_4_145_1","unstructured":"Jiangsu Hengrui Pharmaceutical Co. Ltd. Fused tetracyclic compound preparation method thereof and application thereof in medicinep. WO2022199676A1. 2022."},{"key":"e_1_3_4_146_1","unstructured":"Betta Pharmaceuticals Co. Ltd. HPK1 inhibitor and application thereof in medicineWO2022228489A1. 2022."},{"key":"e_1_3_4_147_1","unstructured":"Unacon Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. Cyclic compound preparation and application thereof. CN116731029A. 2023."},{"key":"e_1_3_4_148_1","article-title":"Azaindazole macrocyclic compound and use thereof","author":"Broadenbio Co. Ltd","year":"2023","unstructured":"Broadenbio Co. Ltd. Azaindazole macrocyclic compound and use thereof. CN115838373A. 2023.","journal-title":"CN115838373A"},{"key":"e_1_3_4_149_1","unstructured":"Broadenbio Co. Ltd. Azaindazole macrocyclic compound and use thereof. 2023p. WO2023040996A1."},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_4_151_1","unstructured":"Nurix Therapeutics Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofp. WO2021226262A1. 2021."},{"key":"e_1_3_4_152_1","unstructured":"Nurix Therapeutics Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofp. WO2023086399A1. 2023."},{"key":"e_1_3_4_153_1","unstructured":"Beigene Ltd. Pyrrolo[2 3-b]pyrazine-basrd bifunctional compounds as HPK1 degraders and the use thereof. WO2023006063A1. 2023."},{"key":"e_1_3_4_154_1","unstructured":"Icahn School of Medicine at Mount Sina. Heterobifunctional compounds as HPK1 degradants. WO2023097020A1. 2023."},{"key":"e_1_3_4_155_1","unstructured":"Biofront Ltd (Cayman). HPK1 degraders composition the HPK1 degrader and methods of using same. WO2023023941A1. 2023."},{"key":"e_1_3_4_156_1","unstructured":"Biofront Ltd (Cayman). HPK1 degraders compositions thereof and methods of using the same. WO2023025091A1. 2023."},{"key":"e_1_3_4_157_1","unstructured":"Hejing Medical Science and Technology (Shanghai) Co. Ltd. Heterocyclic compound pharmaceutical composition containing the same and anti-tumor application thereof. CN116462685A. 2023."},{"key":"e_1_3_4_158_1","unstructured":"Sichuan Haisike Pharmaceutical Co. Ltd. Compound for inhibiting or degrading HPK1 kinase and medical use thereof. WO2023143384A1. 2023."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2462834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T10:37:04Z","timestamp":1743503824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2462834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,16]]},"references-count":156,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/13543776.2025.2462834"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2462834","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}